Objective To compare the clinicopathological features and prognostic differences between undifferentiated/dedifferentiated endometrial carcinoma (UDEC) and FIGO histological grade 3 (G3) endometrioid endometrial carcinoma (EEC). Methods Clinicopathological data from 91 UDEC and 251 G3 EEC cases were retrospectively collected. Molecular classification was performed using immunohistochemistry and gene sequencing, followed by statistical analysis. Results Compared with G3 EEC, patients with UDEC were younger at diagnosis (51.3±10.7 years vs. 56.4±10.9 years), had a higher incidence of extensive lymphovascular space invasion (61.3%, 49/80) and lymph node metastasis (39.8%, 33/83), presented with more advanced 2023 FIGO stages after adjustment by molecular classification (all P<0.001), and had a higher disease-specific mortality rate (χ2=14.33, P<0.001). Additionally, UDEC showed higher proportions of mismatch repair deficiency phenotype (51.4%, 37/72), SMARCA4 mutation (58.8%, 10/17), ER negativity (55.1%, 43/78), PR negativity (50.0%, 38/76), and BRG1 protein loss (49.3%, 34/69) (all P<0.05). SMARCA4 deficiency was associated with worse disease-specific survival only in UDEC (HR=3.56, P=0.011). Conclusions Both UDEC and G3 EEC are highly heterogeneous, and an integrated diagnosis combining pathological features and clinical staging is necessary. UDEC exhibits greater invasiveness, and SMARCA4 deficiency may serve as a complementary marker for its diagnosis and prognosis prediction.